Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17024
Country/Region: South Africa
Year: 2016
Main Partner: Foundation for Professional Development
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $317,040 Additional Pipeline Funding: $2,056,234

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $50,000
Care: TB/HIV (HVTB) $40,000
Care: Pediatric Care and Support (PDCS) $50,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $10,000
Treatment: Adult Treatment (HTXS) $117,040
Treatment: Pediatric Treatment (PDTX) $50,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 545
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 363
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 3,083
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 2,055
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 6,049
HTS_TST Service Delivery Point (Facility): Inpatient 2017 605
HTS_TST Service Delivery Point (Facility): Outpatient 2017 5,444
HTS_TST Sum of Aggregated Age/Sex <15 2017 908
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 5,138
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 6,046
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 70
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 43
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 388
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 257
PMTCT_ART Already on ART at beginning of current pregnancy 2017 161
PMTCT_ART New on ART 2017 108
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,510
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 295
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 3
PMTCT_EID Sum of Infant Age disaggregates 2017 295
PMTCT_STAT By: Known positives at entry 2017 606
PMTCT_STAT By: Number of new positives identified 2017 905
PMTCT_STAT Number of new ANC and L&D clients 2017 1,540
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,510
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,511
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 15
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 79
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 54
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 176
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 158
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 85
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 3
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 8
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 73
TB_SCREENDX Screen Results: Screened Positive for TB 2017 96
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 8
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 4
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 48
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 32
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 4,772
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 26
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 148
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 18
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 101
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 293
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 307
TX_CURR Aggregated Age/Sex: <15 Female 2017 414
TX_CURR Aggregated Age/Sex: <15 Male 2017 276
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,350
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,567
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 4,610
TX_CURR Sum of Aggregated Age/Sex <15 2017 690
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 3,917
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 4,607
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 108
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 72
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 614
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 401
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,206
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,195
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 4,148
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 3,735
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 336
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 224
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 1,905
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,269
TX_PVLS Numerator: Indication: Routine 2017 3,359
TX_PVLS Numerator: Indication: Targeted 2017 373
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 230
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 152
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,299
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 865
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,542
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,707
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 50
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 33
Cross Cutting Budget Categories and Known Amounts Total: $130,000
Human Resources for Health $120,000
Gender: Gender Based Violence (GBV) $10,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation